查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2003200

进行性遗传性肝内胆汁淤积症 (PFIC) 治疗市场：2026 年至 2032 年全球市场预测（按治疗方法、药物类别、给药途径、患者年龄组、PFIC 类型、最终用户和分销渠道划分）

Progressive Familial Intrahepatic Cholestasis Treatment Market by Treatment Type, Drug Class, Route Of Administration, Patient Age Group, PFIC Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，进行性遗传性肝内胆汁淤积症 (PFIC) 的治疗市场价值将达到 1.244 亿美元，到 2026 年将增长到 1.2987 亿美元，到 2032 年将达到 1.7281 亿美元，复合年增长率为 4.80%。

主要市场统计数据
基准年 2025 1.244亿美元
预计年份：2026年 1.2987亿美元
预测年份 2032 1.7281亿美元
复合年增长率 (%) 4.80%

为提供 PFIC 护理的临床、治疗和操作背景的简明权威概述，并明确所有相关人员。

进行性遗传性肝内胆汁淤积症（PFIC）是一组遗传和临床表现各异的胆汁淤积性肝病，在诊断、临床治疗和长期照护的各个阶段都面临着复杂的挑战。患者自婴儿早期起便出现进行性肝功能障碍，通常需要药物治疗、支持性治疗以及在许多情况下需要手术介入的综合治疗方案。因此，临床医生、研究人员和医疗保健系统正在寻求多管齐下的策略，以平衡短期症状控制和从根本上改变疾病发病机制的长期治疗方案。

新的治疗方法、适应性监管方法和综合护理模式的融合正在重新定义 PFIC（生理性精神感染）的治疗范式和引入途径。

近年来，科学、监管和医疗服务等多面向因素的共同作用，为进行性家族性肝内胆汁淤积症（PFIC）领域带来了变革性的变化。分子遗传学的进步和对胆汁酸生理学更深入的理解，加速了标靶药物疗法的研发，这些药物能够直接调节肠肝循环。这项发展使得治疗选择不再局限于缓解症状的支持性疗法，而是扩展到能够改变疾病进程、延缓甚至避免侵入性手术干预的药物。

本研究评估了美国计划于 2025 年实施的关税措施对 PFIC 治疗的供应链、临床项目、采购和患者获取途径的影响。

美国近期宣布的2025年关税措施，透过影响跨境供应链的经济和物流环节，为被动真菌感染（PFIC）治疗生态系统带来了新的复杂性。许多特种药品、原料和生物製药都依赖国际生产和分销网络。随着关税增加活性成分、成品或辅助设备的采购成本，赞助商和经销商将面临重新评估筹资策略、库存管理以及与生产合作伙伴的合约条款的压力。

整合细分情报，揭示治疗类型、药物分类、医疗保健环境、分销管道、途径、年龄层和 PFIC 亚型如何影响策略和实施。

在进行性家族性肝内胆汁淤积症 (PFIC) 的治疗过程中，由于治疗方案涉及不同的治疗分类、临床环境和患者群体，因此，以患者群体为导向的决策对于个性化开发和商业化至关重要。就治疗类型而言，药物治疗是缓解疾病和症状管理临床策略的核心，其中胆汁酸吸附剂和髂骨胆汁酸转运体抑制剂作为标靶机制尤为重要。在药物治疗中，胆汁酸吸附剂（如考来烯胺和考来维崙）在缓解症状和改善生化指标方面发挥作用，而迴肠胆汁酸转运体抑製剂（如马拉利昔瓦和奥德比昔瓦）旨在减少毒性胆汁酸的积累。利福平和熊去氧胆酸等辅助治疗药物在缓解症状和改善生化指标方面也仍然十分重要。支持治疗仍然至关重要，营养支持和症状管理对于维持生长和生活品质至关重要。同时，从胆道旁路手术到肝臟移植等外科手术，为难治性或进行性疾病的逐步升级治疗提供了选择。

美洲、欧洲、中东、非洲和亚太地区在临床网路、支付方框架和医疗保健基础设施方面的区域差异正在影响医疗服务的取得和采用趋势。

区域趋势对进行性家族性肝内胆管炎（PFIC）治疗方法的研发、实施和报销有显着影响，美洲、欧洲、中东、非洲和亚太地区之间存在显着差异，进而影响临床实践模式和治疗途径。在美洲，集中化的高品质医疗中心、完善的移植网络和成熟的专科药房管道为新治疗方法的早期应用提供了支持。然而，保险公司越来越要求提供可靠的真实世界数据和长期疗效数据，以证明高昂治疗费用的合理性。在此背景下，能够证明患者获益清晰，并建立包含移植项目和儿童肝病中心在内的综合诊疗路径的申办方将更具优势。

创新公司、专业製药公司和临床网路如何协调其研发、伙伴关係和商业策略，以塑造其在 PFIC 领域的竞争地位和市场接受度？

在PFIC（持续性、功能性、免疫和免疫）领域，专业化、策略伙伴关係和适应性商业化策略是企业竞争定位的关键要素。开发标靶治疗的创新公司通常与临床中心和学术网络合作，设计临床试验，以捕捉诸如瘙痒减轻、生化指标改善和非移植生存率等有意义的终点指标。专业製药公司和生物製药开发公司透过製剂科学、适合儿童的给药途径以及满足监管机构和支付方需求的数据生成计划来脱颖而出。同时，医疗服务提供者和移植中心在支持协作式照护路径方面发挥越来越重要的策略作用，这些路径有助于建立登记系统、追踪长期疗效并引入新的治疗方法。

采取切实有效的领导行动，协调证据产生、供应弹性和商业策略，以加速 PFIC治疗方法的引入并改善患者预后。

产业领导者必须采取一系列合作措施，以确保PFIC领域的科学进步能够转化为可持续的临床和商业性影响。首先，研发项目应优先考虑能够反映患者真实体验和长期器官保存情况的终点指标，并使试验设计与支付方的证据需求保持一致。其次，申办方应儘早投资于真实世界资料平台和病患登记系统，以便将临床试验资料与长期疗效联繫起来，并为医保报销谈判和核准后监测提供支援。

采用严谨的混合方法，结合关键相关人员的访谈、临床文献的整合和情境分析，检验了对 PFIC相关人员。

本研究采用多方法整合策略，旨在融合临床专业知识、相关人员的观点以及同侪审查文献的证据。主要研究包括对临床医生、移植外科医生、专科药剂师和支付方代表进行结构化访谈，以了解治疗方法选择、物流供应和报销方面的实际考虑。这些定性资讯被用于对近期临床文献进行系统性回顾和检验，以识别PFIC研究中使用的新型治疗机制、相关安全考量和试验终点。

策略整合突显了将治疗创新转化为 PFIC 患者疗效的永续改善所必需的条件和协作努力。

在科学进步、不断发展的医疗模式和不断变化的经济限制因素的推动下，进行性胆汁淤积性肝病 (PFIC) 的治疗格局正处于转折点。标靶调节胆汁酸代谢的疗法、完善的多学科诊疗网络以及适应性强的监管流程共同作用，为改善进行进行性胆汁淤积性肝病患者的预后创造了机会。然而，实现这些益处需要各方通力合作：一方面需要提供强有力的证据以赢得监管机构和支付方的认可；另一方面需要製定供应链策略以降低外部风险；此外，还需要製定能够反映终端用户需求和当地医疗体系特点的精准商业化计划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场（依治疗方法划分）

  • 药物治疗
    • 抗生素
    • 胆汁酸吸附剂
      • 考来烯胺
      • 核心
    • IBAT抑制剂
      • 马拉利希巴特
      • 奥德比·基斯巴特
    • 利福平
    • 熊去氧胆酸
  • 支持性护理
    • 营养支持
    • 症状管理
  • 手术介入
    • 胆道绕道手术
    • 肝臟移植

第九章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依药物类别划分

  • 抗生素
  • 胆汁酸吸附剂
    • 考来烯胺
    • 核心
  • IBAT抑制剂
    • 马拉利西巴特
    • 奥德比·基斯巴特
  • 熊去氧胆酸

第十章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依给药途径划分

  • 静脉
  • 口服

第十一章 依病患年龄组别分類的进行性遗传性肝内胆汁淤积症 (PFIC) 治疗市场

  • 青年
  • 成人
  • 儿童

第十二章进行性遗传性肝内胆汁淤积症 (PFIC) 治疗市场（按 PFIC 类型划分）

  • 一型
  • II 型
  • III型

第十三章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十四章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十五章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章进行性遗传性肝内胆汁淤积症（PFIC）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国进行性遗传性肝内胆汁淤积症（PFIC）进行性市场

第十九章：中国进行性遗传性肝内胆汁淤积症（PFIC）进行性市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie, Inc.
  • Albireo Pharma, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mirum Pharmaceuticals, Inc.
  • Novartis International AG
  • Par Pharmaceutical Companies, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-AD517FAAA5F2

The Progressive Familial Intrahepatic Cholestasis Treatment Market was valued at USD 124.40 million in 2025 and is projected to grow to USD 129.87 million in 2026, with a CAGR of 4.80%, reaching USD 172.81 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 124.40 million
Estimated Year [2026] USD 129.87 million
Forecast Year [2032] USD 172.81 million
CAGR (%) 4.80%

A concise and authoritative overview of the clinical, therapeutic, and operational context for PFIC care that frames strategic priorities across stakeholders

Progressive familial intrahepatic cholestasis (PFIC) represents a set of genetically and clinically heterogeneous cholestatic liver disorders that present complex challenges across diagnosis, clinical management, and long-term care. Patients encounter progressive liver dysfunction from early life onward, often requiring a mix of pharmacologic approaches, supportive interventions, and in many cases surgical procedures. Clinicians, researchers, and health systems are therefore pursuing multimodal strategies that balance immediate symptom control with durable approaches that alter disease biology.

This executive summary frames the contemporary landscape for PFIC treatment by synthesizing developments across therapeutic modalities, regulatory pathways, and care delivery models. It highlights the drivers reshaping clinical priorities, such as new targeted agents designed to reduce intrahepatic bile acid burden, evolving standards for liver transplantation and diversion procedures, and the maturation of specialist care networks. The narrative also emphasizes the importance of aligning clinical innovation with supply chain resilience, payer engagement, and patient-centered care models to ensure that advanced therapies translate into equitable real-world benefit. By setting this context, the introduction prepares the reader for a deeper exploration of transformative shifts, segmentation intelligence, regional considerations, and tactical recommendations aimed at stakeholders across the therapeutic ecosystem.

Emerging therapeutic innovations, adaptive regulatory approaches, and integrated care models converging to redefine treatment paradigms and adoption pathways for PFIC

Over the last several years, a confluence of scientific, regulatory, and care-delivery forces has produced transformative shifts in the PFIC landscape. Advances in molecular genetics and a deeper understanding of bile acid physiology have accelerated the development of targeted pharmacotherapies that directly modulate enterohepatic bile acid circulation. This evolution has expanded options beyond symptom-directed supportive care toward agents that may alter disease trajectory and delay or obviate the need for invasive surgical interventions.

At the same time, clinical practice has begun to embrace more integrated care models that combine specialized hepatology centers, coordinated nutritional support, and earlier referral pathways for transplant evaluation. Regulatory authorities have increasingly offered adaptive pathways and orphan-drug incentives that shorten timelines for therapies addressing ultra-rare diseases, while payers and health systems are refining value frameworks to assess long-term benefits versus upfront costs. The combination of improved diagnostics, a growing pipeline of targeted agents, and evolving reimbursement dialogues has shifted strategic imperatives: sponsors must now plan for differentiated clinical programs, a clear evidence generation strategy for payers, and partnerships with specialty clinics and transplant centers to support adoption and patient monitoring.

Evaluating how United States tariff measures slated for 2025 are poised to affect supply chains, clinical programs, procurement, and patient access for PFIC therapies

Recent tariff actions announced for 2025 within the United States create a new layer of complexity for the PFIC therapeutic ecosystem by affecting the economics and logistics of cross-border supply chains. Many specialized medicines, raw materials, and biologic components rely on international manufacturing and distribution networks. When tariffs increase the landed cost of active pharmaceutical ingredients, finished products, or ancillary devices, sponsors and distributors face pressure to reassess sourcing strategies, inventory practices, and contractual terms with manufacturing partners.

These cost pressures can ripple through procurement practices among hospitals, specialty clinics, and pharmacy channels, compelling tighter negotiations with manufacturers and more stringent evaluation of formulary placements. Clinical development programs are also affected: trial supply budgets, import/export timelines, and site selection may need realignment to maintain continuity of investigational product delivery. In response, stakeholders are prioritizing supply-chain diversification, near-shoring of critical manufacturing steps where feasible, and enhanced demand forecasting to reduce exposure to tariff volatility. Payer engagement strategies must similarly incorporate the implications of higher acquisition costs, focusing on health economic arguments that emphasize downstream reductions in hospitalization or transplantation needs. Overall, the tariff environment underscores the need for strategic planning that minimizes disruption while preserving timely patient access to essential PFIC therapies.

Integrated segmentation intelligence revealing how treatment types, drug classes, care settings, channels, routes, age cohorts, and PFIC subtypes shape strategy and execution

Segment-driven decisioning is essential for tailored development and commercialization in PFIC because the therapeutic journey spans distinct treatment classes, care settings, and patient cohorts. When considering treatment type, pharmacotherapy dominates clinical strategy for disease modification and symptom control, with topical emphasis on bile acid sequestrants and inhibitors of the ileal bile acid transporter as targeted mechanisms. Within pharmacotherapy, bile acid sequestrants such as cholestyramine and colesevelam serve symptomatic and biochemical roles, while IBAT inhibitors-represented by agents like maralixibat and odevixibat-are designed to reduce toxic bile acid accumulation. Complementary options such as rifampicin and ursodeoxycholic acid retain roles in symptom mitigation and biochemical improvement. Supportive care remains foundational, with nutritional support and symptom management critical to maintaining growth and quality of life, while surgical interventions ranging from biliary diversion procedures to liver transplantation provide escalation pathways for refractory or progressive disease.

Drug-class considerations further refine prioritization, with distinctions between antibiotics, sequestrants, IBAT inhibitors, and bile acid modulators influencing clinical trial endpoints, safety monitoring, and commercialization narratives. End-user segmentation highlights the differing needs of homecare environments, hospital inpatient services, and specialty clinic networks, each requiring tailored distribution, education, and adherence support. Distribution-channel choices-including hospital pharmacies, online dispensaries, and retail pharmacies-determine how therapies reach patients and how supply assurance must be managed. Route of administration differentiates products that are oral from those requiring intravenous delivery, shaping adherence strategies and clinical support requirements. Age-group segmentation across children, adolescents, and adults mandates age-appropriate formulations and dosing strategies, while PFIC subtype distinctions among Type I, Type II, and Type III drive molecularly targeted approaches, trial inclusion criteria, and long-term outcome expectations. Synthesizing these segments enables more precise patient identification, clinical pathway design, and go-to-market strategies tailored to the complex realities of PFIC care.

Regional differences in clinical networks, payer frameworks, and healthcare infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption dynamics

Regional dynamics significantly influence how PFIC therapies are developed, adopted, and reimbursed, with important distinctions across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect clinical practice patterns and access pathways. In the Americas, concentrated centers of excellence, established transplantation networks, and mature specialty pharmacy channels support early adoption of novel therapies, yet payers increasingly demand robust real-world evidence and longitudinal outcomes to justify coverage for high-cost interventions. This environment favors sponsors that can demonstrate clear patient-level benefits and create integrated care pathways involving transplant programs and pediatric hepatology centers.

In Europe Middle East & Africa, fragmented regulatory frameworks and variable reimbursement landscapes require differentiated market access approaches. Nations with centralized health technology assessment bodies emphasize health-economic modeling and comparative-effectiveness evidence, while other jurisdictions may leverage managed access agreements to enable early patient access. Specialty clinics and hospital systems play a vital role in coordinating care and delivering complex interventions. Across the Asia-Pacific region, heterogeneity in healthcare infrastructure, variable access to transplantation, and differing regulatory expectations necessitate flexible clinical and commercial plans. Some markets are accelerating adoption through expanded orphan-disease programs, while others prioritize capacity-building for diagnosis and specialist care. Taken together, regional strategies must account for differences in clinical networks, payer expectations, supply logistics, and the relative maturity of specialty pharmacy channels to achieve effective and equitable access for PFIC patients.

How innovators, specialty manufacturers, and clinical networks are aligning R&D, partnerships, and operational strategies to shape competitive positioning and adoption in PFIC

Company-level dynamics in PFIC combine specialization, strategic partnerships, and adaptive commercialization strategies as essential elements of competitive positioning. Innovators developing targeted agents often partner with clinical centers and academic networks to design trials that capture meaningful endpoints such as pruritus reduction, biochemical improvement, and transplantation-free survival. Specialty pharmaceutical firms and biologic developers differentiate through formulation science, pediatric-friendly administration routes, and data generation plans that address both regulators and payers. Meanwhile, providers and transplant centers increasingly act as strategic partners, supporting registry development, long-term outcome tracking, and coordinated care pathways that facilitate adoption of novel therapies.

Collaborations between manufacturers, contract development and manufacturing organizations, and specialty distributors are also central to maintaining supply continuity for niche therapeutic products. Strategic alliances that enable shared manufacturing capacity, regional distribution hubs, and integrated patient support services reduce time-to-patient and mitigate risks from supply disruptions. Companies that invest in robust post-approval evidence generation-including natural history studies and real-world registries-build stronger value propositions for payers. Finally, competitive strategies that combine clinical differentiation with demonstrable operational readiness, such as patient support programs and clinician education initiatives, tend to accelerate uptake and reinforce long-term position in the PFIC therapeutic space.

Practical, high-impact actions for leaders to align evidence generation, supply resilience, and commercial strategies to accelerate adoption and improve patient outcomes in PFIC

Industry leaders must adopt a coordinated set of actions to ensure that scientific advances in PFIC translate into sustained clinical and commercial impact. First, development programs should prioritize endpoints that reflect meaningful patient experiences and long-term organ preservation, aligning trial designs with payer evidence needs. Sponsors should also invest early in real-world evidence platforms and patient registries that can bridge clinical trial data to long-term outcomes, supporting reimbursement negotiations and post-authorization monitoring.

Operationally, diversifying manufacturing and distribution arrangements will reduce exposure to tariff-induced price pressures and logistical delays, while strategic partnerships with specialty pharmacies and homecare providers will enable more reliable patient access. Commercial strategies must be nuanced for different end users, with tailored educational programs for hospitals and specialty clinics, adherence and support offerings for homecare patients, and streamlined access pathways for retail and online pharmacy channels. Additionally, prioritizing pediatric-friendly formulations and administration routes will support broader adoption across age cohorts. Lastly, fostering closer collaboration with transplant centers and multidisciplinary care teams will ensure that escalation pathways remain fit-for-purpose and that new therapies are integrated into comprehensive care plans that improve patient quality of life and long-term outcomes.

A rigorous mixed-methods approach combining primary stakeholder interviews, clinical literature synthesis, and scenario analysis to validate actionable insights for PFIC stakeholders

This research synthesis is grounded in a multi-method approach designed to integrate clinical expertise, stakeholder perspectives, and evidence from peer-reviewed literature. Primary research included structured interviews with clinicians, transplant surgeons, specialty pharmacists, and payer representatives to capture practical considerations around treatment selection, supply logistics, and reimbursement. These qualitative inputs were triangulated with systematic review of recent clinical literature to identify emerging therapeutic mechanisms, relevant safety considerations, and trial endpoints used in PFIC studies.

Operational and commercial insights were informed by analysis of distribution practices and care-delivery models across hospital, specialty clinic, and homecare settings, along with examination of formulation and route-of-administration constraints that affect adherence and patient experience. Supply-chain implications were assessed through scenario analysis that considered tariff impacts, cross-border manufacturing dependencies, and mitigation strategies such as near-shoring and redundant sourcing. Throughout the process, findings were validated through follow-up consultations with key opinion leaders and clinical program managers to ensure that recommendations are practical, clinically relevant, and aligned with current regulatory and payer expectations. This methodology prioritizes rigor, stakeholder relevance, and applicability to real-world decision-making.

A strategic synthesis highlighting the conditions and collaborative actions required to convert therapeutic innovation into sustainable improvements in PFIC patient outcomes

The PFIC treatment landscape is at an inflection point driven by scientific advances, evolving care models, and shifting economic constraints. Targeted pharmacotherapies that modulate bile acid handling, improvements in clinical networks for multidisciplinary care, and adaptive regulatory pathways collectively create an opportunity to improve outcomes for patients facing progressive cholestatic liver disease. Yet realizing these benefits requires coordinated action: robust evidence generation that speaks to regulators and payers, supply-chain strategies that mitigate external risks, and targeted commercialization plans that reflect the nuances of end-user needs and regional healthcare systems.

Stakeholders who align clinical development with pragmatic operational readiness and payer-centered value demonstration will be best positioned to translate therapeutic potential into measurable patient benefit. Equally important is the cultivation of partnerships across manufacturers, specialty clinics, transplant centers, and patient advocacy networks to ensure that access pathways are equitable and sustainable. If these elements are addressed in concert, the community can move toward earlier intervention, reduced morbidity, and improved long-term outcomes for individuals living with PFIC.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Treatment Type

  • 8.1. Pharmacotherapy
    • 8.1.1. Antibiotics
    • 8.1.2. Bile Acid Sequestrants
      • 8.1.2.1. Cholestyramine
      • 8.1.2.2. Colesevelam
    • 8.1.3. Ibat Inhibitors
      • 8.1.3.1. Maralixibat
      • 8.1.3.2. Odevixibat
    • 8.1.4. Rifampicin
    • 8.1.5. Ursodeoxycholic Acid
  • 8.2. Supportive Care
    • 8.2.1. Nutritional Support
    • 8.2.2. Symptom Management
  • 8.3. Surgical Interventions
    • 8.3.1. Biliary Diversion
    • 8.3.2. Liver Transplantation

9. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Class

  • 9.1. Antibiotics
  • 9.2. Bile Acid Sequestrants
    • 9.2.1. Cholestyramine
    • 9.2.2. Colesevelam
  • 9.3. Ibat Inhibitors
    • 9.3.1. Maralixibat
    • 9.3.2. Odevixibat
  • 9.4. Ursodeoxycholic Acid

10. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Patient Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Children

12. Progressive Familial Intrahepatic Cholestasis Treatment Market, by PFIC Type

  • 12.1. Type I
  • 12.2. Type II
  • 12.3. Type III

13. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End User

  • 13.1. Homecare
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Progressive Familial Intrahepatic Cholestasis Treatment Market

19. China Progressive Familial Intrahepatic Cholestasis Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie, Inc.
  • 20.6. Albireo Pharma, Inc.
  • 20.7. Alexion Pharmaceuticals, Inc.
  • 20.8. Amgen Inc.
  • 20.9. AstraZeneca PLC
  • 20.10. Biocon Limited
  • 20.11. Boehringer Ingelheim International GmbH
  • 20.12. Bristol-Myers Squibb Company
  • 20.13. Cipla Limited
  • 20.14. Eisai Co., Ltd.
  • 20.15. F. Hoffmann-La Roche Ltd
  • 20.16. Gilead Sciences, Inc.
  • 20.17. Glenmark Pharmaceuticals Limited
  • 20.18. Ipsen Pharma
  • 20.19. Johnson & Johnson
  • 20.20. Merck & Co., Inc.
  • 20.21. Mirum Pharmaceuticals, Inc.
  • 20.22. Novartis International AG
  • 20.23. Par Pharmaceutical Companies, Inc.
  • 20.24. Pfizer Inc.
  • 20.25. Sanofi S.A.
  • 20.26. Takeda Pharmaceutical Company Limited
  • 20.27. Teva Pharmaceutical Industries Ltd.
  • 20.28. Viatris Inc.
  • 20.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC